UroXatral launch
Executive Summary
Sanofi expects to launch UroXatral (once-daily alfuzosin) for benign prostatic hyperplasia treatment in 2003; Sanofi and SkyePharma received an "approvable" letter from FDA in October 2001 (1"The Pink Sheet" Oct. 15, 2001, In Brief)...
You may also be interested in...
SkyePharma/Sanofi UroXatral "approvable"
Sanofi-Synthelabo and SkyePharma expect to launch UroXatral (once-daily alfuzosin) in 2002, Sanofi says following Oct. 5 "approvable" letter from FDA. European version of benign prostatic hyperplasia treatment was approved in January as Xatral OD
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.